Size-based gating for analyzing flow cytometry data
The method of digital sorting and gating based on size and biomarker expression in flow cytometry simplifies the analysis of heterogeneous tumor samples, enhancing data quality and enabling accurate quantification of cell types.
Patent Information
- Application Number
- JP2023061221
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-20
- Filing Date
- 2023-04-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-09-18
AI Technical Summary
Current flow cytometry methods struggle with analyzing heterogeneous tumor samples due to complex data interpretation from mixed cell populations, leading to obscured subpopulations and difficulty in distinguishing cell types, especially when a minority subpopulation is present.
A method involving digital sorting and gating based on cell size and granularity correlations, followed by secondary gating for biomarker expression, to separate homogeneous cell populations from heterogeneous tumor samples, allowing for efficient data analysis without physical sorting.
This approach simplifies data analysis by providing homogeneous cell populations, improving data quality and enabling accurate quantification of specific cell types, facilitating better treatment decisions and correlation analysis.
Smart Images

Figure 0007590487000001 
Figure 0007590487000002 
Figure 0007590487000003
Abstract
Description
[Technical field]
[0001] Cancer is a disease characterized by the unregulated proliferation of abnormal cells. In normal tissues, cells divide and organize within the tissue in response to signals from surrounding cells, resulting in normal cellular behaviors that are carefully regulated by the tissue context. Cancer cells do not respond to growth-limiting contextual cues from the surrounding tissues and often harbor genetic alterations that drive their proliferation and lead to the formation of tumors in many organs. As tumor growth progresses, genetic and phenotypic alterations continue to accumulate, allowing populations of cancer cells to overcome further "checkpoints," such as antitumor immune responses, and manifest as a more aggressive proliferation phenotype of cancer cells. If left untreated, metastasis can occur, where cancer cells spread to distant parts of the body via the lymphatic system or bloodstream. Metastasis forms secondary tumors at multiple sites and damages healthy tissue. Most cancer deaths are caused by such secondary tumors. [Background technology]
[0002] Despite decades of progress in cancer diagnosis and treatment, many cancers remain undetected until late in their development. As a result, many solid tumors at the initial site of growth often contain spatially separated genetically and / or phenotypically heterogeneous tumor cell populations. One or more of these cancer cell populations within the primary tumor can give rise to secondary metastatic tumors. Moreover, the tumor mass is often composed of normal cells that are either recruited by the tumor to form a supportive environment (e.g., blood vessels) or that were initially attracted to the tumor by the host (e.g., immune cells) as a defense mechanism, but were later overcome as the cancer evolved.
[0003] One technique for computing, examining, and sorting multiple analytes, including cell populations, occurring in biological samples, such as tumor samples or samples derived from tumor masses, includes flow cytometry. Flow cytometry allows for simultaneous multiparametric analysis of the physical and / or chemical characteristics of particles flowing through an optical and / or electronic detection device. Current optical detection systems monitor changes in light scattering and fluorescence. Electronic detection is achieved by suspending particles in a conductive fluid and then passing them through a small opening or orifice. An electronic field is applied across the opening or orifice, generating an electric current. As a particle passes through the opening, the resistance across the orifice increases. The increase in resistance at a constant current results in an increase in voltage across the orifice, which is directly related to the volume of the particle. A measurable voltage pulse is generated, which can be analyzed and used to perform further manipulations, such as particle conductivity, resistivity, capacitance, and shape modeling. Summary of the Invention
[0004] Applicant has developed a new approach to sampling tumors so that meaningful information can be obtained from the sampled tumor. Applicant has shown that cells dissociated from homogenized whole tumor samples are relatively representative of different cell types from the whole tumor, for example, homogenized whole tumor samples are composed of a heterogeneous collection of cells or cell populations including tumor cells, immune cells, stromal cells, etc. (See, e.g., PCT Publication Nos. PCT / US2016 / 060861 and PCT / US2016 / 060835, the disclosures of which are incorporated herein by reference in their entirety). Similarly, Applicant has shown that the remaining surgical material from fixed tumors can be mixed and dissociated into single cells for further downstream analysis by flow cytometry.
[0005] When presented for flow cytometry analysis, more representative information is provided, but the heterogeneous population of cell types (homogenate-derived) makes data analysis relatively complex. For example, certain cell subpopulations (e.g., CD8-positive ones) can be plotted on the same density plot graph as other cell types, and their detection in a heterogeneous mixture can be obscured if the subpopulation represents a minority of cells in the homogenate (see, e.g., FIG. 6). This is also rooted in the fact that flow cytometry is traditionally used to analyze more homogeneous cell populations, such as peripheral blood mononuclear cells (PBMCs) (compare FIG. 5A with FIG. 6). Thus, data presented from flow cytometry for homogenate-derived samples is considered to be unfamiliar to those skilled in the art and relatively difficult to interpret.
[0006] Applicant has developed a method to reduce the complexity of flow cytometry data from heterogeneous samples, for example from whole tumor samples. Applicant has developed a method of digital sorting or gating, whereby a heterogeneous mixture of tumor and normal cell particles (including immune cells) can be separated into well-defined populations (e.g., tumor or normal cell populations) to increase efficiency in research, tumor analysis, and other downstream processing tasks. The gating strategies described herein provide substantially homogenous populations and subpopulations that are easily analyzed, resulting in improved data quality and the ability to derive correlations between different subsets of data.
[0007] In one aspect of the disclosure, the method is a method of quantifying the percentage of cells expressing one or more biomarkers, comprising homogenizing a whole tumor sample to provide a homogenized sample, dissociating single cells from the homogenate, staining the cells in the homogenized sample for the presence of one or more biomarkers, performing at least a first primary gating of cells in the homogenized sample based on forward scatter (correlated with cell size) and backscatter (correlated with cell granularity) to provide at least a first cell population having a first predicted cell type, and determining the percentage of cells expressing a first of the one or more biomarkers in a first subpopulation within the first cell population. In some embodiments, the method does not require a physical sorting step prior to determining the percentage of cells in at least the first cell subpopulation.
[0008] In some embodiments, the first predicted cell type is an immune cell. In some embodiments, the immune cell is less than about 12 μm in size. In some embodiments, the homogenized tissue sample is processed prior to staining, and the further processing comprises at least one of digesting proteins within the homogenized sample, heating the sample, or filtering the homogenized sample.
[0009] In some embodiments, the percentage of the first cells in the first subpopulation that express a first of the one or more biomarkers is determined by secondary gating of cells in the first population based on the presence of a first of the one or more biomarkers, in some embodiments, the first of the one or more biomarkers is selected from the group consisting of the CD3, CD4, CD8, CD25, CD163, CD45LCA, CD45RA, and CD45RO cluster of differentiation biomarkers.
[0010] In some embodiments, the method further comprises determining a percentage of cells in a second subpopulation within the first cell population that express a second of the one or more biomarkers, wherein the first and second of the one or more biomarkers are different. In some embodiments, the second of the one or more biomarkers is a cluster of differentiation markers. In some embodiments, the second of the one or more biomarkers is a biomarker other than a cluster of differentiation biomarkers. In some embodiments, the second of the one or more biomarkers is selected from the group consisting of PD-1, TIM-3, LAG-3, CD28, CD57, and FOXP3, EPCAM, CK8 / 18. In some embodiments, the first of the one or more biomarkers is CD3 and the second of the one or more biomarkers is a biomarker that differentiates immune cells as regulatory T cells, helper T cells, or cytotoxic T cells.
[0011] In some embodiments, the method further comprises performing a second primary gating of cells in the homogenized sample to provide at least a second cell population of cells having a second predicted cell type. In some embodiments, the second predicted cell type is a tumor cell. In some embodiments, the method further comprises determining a percentage of cells in the second cell population of cells having a chromosomal abnormality. In some embodiments, the method further comprises correlating the determined percentage of cells having a chromosomal abnormality (e.g., aneuploidy) with a determined percentage of cells expressing a first of one or more biomarkers (e.g., correlation between CD8 positive cells and aneuploid cells).
[0012] In some embodiments, the method further includes making a treatment decision based in part on the determined proportion of cells in the first subpopulation that express a first of the one or more biomarkers.
[0013] In another aspect of the disclosure, the method is a method of quantifying a proportion of cells expressing at least a first biomarker of a plurality of biomarkers in a tissue sample, comprising homogenizing the tissue sample to provide a homogenized sample, staining cells in the homogenized sample for the presence of the plurality of biomarkers, performing a primary gating of cells in the homogenized sample based on scatter to provide at least a first cell population having a first predicted size range, performing at least one secondary gating of cells in the first population, the at least one secondary gating being based on the presence of the at least a first biomarker of the plurality of biomarkers and providing a first cell subpopulation expressing the first biomarker, and determining a proportion of cells in the first cell subpopulation that express the first biomarker of the plurality of biomarkers. In some embodiments, the method does not require a physical sorting step prior to determining the proportion of those cells in the first subpopulation. In some embodiments, the first cell population is gated (ie, selected) based on their forward and back scatter (ie, size and granularity).
[0014] In some embodiments, the homogenized sample is stained for the presence of at least the CD3 biomarker. In some embodiments, the homogenized sample is further stained for the presence of at least one additional cluster of differentiation biomarkers. In some embodiments, at least one secondary gating is performed based on the presence of the CD3 biomarker (e.g., a density plot of forward scattering (FSC) versus CD3 staining intensity). In some embodiments, a separate secondary gating is performed independently based on the presence of the CD3 biomarker and at least one of the CD4 and / or CD8 biomarkers to provide a CD3 subpopulation and at least one of the CD4 and / or CD8 subpopulations. In some embodiments, the percentage of cells in the CD3 subpopulation and at least one of the CD4 and / or CD8 subpopulations are independently determined / quantified.
[0015] In some embodiments, the tissue sample is from at least one of a whole tumor, a partial tumor, a metastatic tumor, a partial metastatic tumor, or a lymph node. In some embodiments, the tissue sample is from at least one of residual surgical material or a biopsy sample. In some embodiments, the homogenized tissue sample is processed prior to staining, and the further processing comprises at least one of digesting proteins within the homogenized sample, heating the sample, or filtering the homogenized sample.
[0016] In some embodiments, the plurality of biomarkers is selected from the group consisting of the cluster of differentiation biomarkers, PD-1, TIM-3, LAG-3, and FOXP3. In some embodiments, the cluster of differentiation biomarkers is selected from the group consisting of CD3, CD4, CD8, CD45RA, CD45RO, CD28, and CD57.
[0017] In another aspect of the disclosure, the method is a method of quantifying the percentage of cells expressing at least a first of one or more biomarkers in a homogenized tissue sample, comprising dissociating the homogenized sample into single cells (e.g., including further mixing and filtering) to obtain a sample made of single cells (e.g., a sample containing primarily single cells), staining the cells for the presence of one or more biomarkers, probing the cells with a flow cytometer, and analyzing the resulting data. In some embodiments, the data analysis comprises performing at least two successive gating steps to obtain at least a first subpopulation of cells expressing the first of the one or more biomarkers, and determining the percentage of cells in the first subpopulation that express the first of the one or more biomarkers.
[0018] In some embodiments, the at least two successive gatings include a primary gating to provide a first cell population and a secondary gating to provide a first cell subpopulation. In some embodiments, the primary gating is based on forward scatter and side scatter. In some embodiments, cutoffs are selected for forward scatter and side scatter such that the first population is enriched with immune cells. In some embodiments, multiple secondary gatings are performed.
[0019] In some embodiments, the secondary gating is performed on at least two clusters of differentiation biomarkers. In some embodiments, the clusters of differentiation biomarkers are selected from the group consisting of CD3, CD4, CD8, CD45RA, CD45RO, CD28, and CD57. In some embodiments, the method further comprises determining a percentage of cells in the second cell subpopulation that express a second of the one or more biomarkers, which is different from the first and second of the one or more biomarkers. In some embodiments, the second of the one or more biomarkers is a biomarker other than the cluster of differentiation markers. In some embodiments, the second of the one or more biomarkers is selected from the group consisting of PD-1, TIM-3, LAG-3, and FOXP3.
[0020] The method of the present disclosure has several clinical applications. In one embodiment, the method can be used to evaluate specific and non-specific immune responses. For example, the method can be used to determine changes in immune function after the development of a tumor, to determine a course of treatment for cancer, or to determine whether an applied treatment is effective. Alternatively, the method can be used to determine changes in immune function after treating a patient with a vaccine, an immunosuppressant, an antiviral agent, an antitumor agent, or other therapeutic agent. [Brief description of the drawings]
[0021] For a general understanding of the features of the present disclosure, reference is made to the drawings, in which like reference numerals are used throughout to identify identical elements.
[0022] [Figure 1] FIG. 1 shows a flow chart for quantifying different cell types in a homogenate according to some embodiments of the present disclosure.
[0023] [Diagram 2] FIG. 2 shows a flow chart for performing continuous gating according to some embodiments of the present disclosure.
[0024] [Diagram 3] FIG. 3 shows a flow chart for quantifying different cell types in a homogenate according to some embodiments of the present disclosure.
[0025] [Figure 4] FIG. 4 shows a flow chart illustrating a process for selecting a gate size according to some embodiments of the present disclosure.
[0026] [Figure 5A] Figure 5A illustrates a CD8 vs. CD4 density plot clearly showing populations of CD4 and CD8 cells, where the sample is derived from a fresh lymphocyte sample. The figure illustrates how the flow cytometry data shows distinct populations (CD4 positive, CD8 positive, and double negative) in a dot plot. The data shown is from an analysis of only immune cells (homogeneous population) from fresh blood (not a cell mixture).
[0027] [Figure 5B] Figure 5B illustrates an FSC vs. CD8 density plot showing the gating of populations of CD8 cells. This figure shows flow cytometry analysis of cells dissociated from a whole tumor (e.g., a highly heterogeneous population of immune, tumor, and epithelial cells). Separate cell populations (circles in the dot plot of Figure 5A) are not shown in Figure 5B, making the data less accessible to users of flow cytometry.
[0028] [Figure 6A] Figure 6A illustrates a density plot (FSC vs. SSC (side scatter)) of a filtered homogenate in which two gatings were selected based on scatter. All filtered cells from the homogenate are illustrated.
[0029] [Figure 6B] FIG. 6B illustrates a density plot (FSC vs. SSC) of the filtered homogenate after primary gating, where only the digitally sorted small cells remain.
[0030] [Figure 7] FIG. 7 illustrates density plots (FSC vs. SSC) of filtered homogenates in which five gates were selected based on scatter.
[0031] [Figure 8A] FIG. 8A illustrates the analysis of gated large cells for the CD3 marker (top two panels). The top right panel shows a control where no primary antibody was added, and the top left panel shows the actual sample. The rectangle in each panel indicates where the positive cells (CD3 positive cells) should be located. The large cells did not show CD3 positivity, which was expected since large cells are mostly tumor cells that do not express the CD3 marker. The bottom panel shows the analysis of small cells for the same CD3 marker. The majority of small cells expressed CD3, which was expected since they were immune cells.
[0032] [Figure 8B]FIG. 8B illustrates the analysis of gated large cells for the CD3 marker (top two panels). The top right panel shows a control where no primary antibody was added, and the top left panel shows the actual sample. The rectangle in each panel indicates where the positive cells (CD3 positive cells) should be located. The large cells did not show CD3 positivity, which was expected since large cells are mostly tumor cells that do not express the CD3 marker. The bottom panel shows the analysis of small cells for the same CD3 marker. The majority of small cells expressed CD3, which was expected since small cells were immune cells.
[0033] [Figure 9A] FIG. 9A illustrates a density plot (FSC versus CD3 staining intensity) for the first subpopulation expressing the CD3 biomarker.
[0034] [Figure 9B] FIG. 9B illustrates a density plot (FSC vs. CD8 staining intensity) for the first subpopulation expressing the CD8 biomarker.
[0035] [Figure 9C] FIG. 9C illustrates a density plot (FSC versus CD4 staining intensity) for the first subpopulation expressing the CD4 biomarker.
[0036] [Figure 10] FIG. 10 shows density plots (FSC vs. CD8 staining intensity) for cell subpopulations derived from different homogenized lung tumor samples.
[0037] [Figure 11] FIG. 11 compares unsorted cells from homogenized tumor samples (Panel C) with CD3 expression after physical sorting (Panel A) and digital sorting (Panel B); both physical and digital sorting improve data quality and allow for derivation of accurate percentile values.
[0038] [Figure 12]FIG. 12 illustrates a method for staining cells derived from a homogenized sample.
[0039] [Figure 13] FIG. 13 illustrates a density plot of CK8 / 18 versus forward scatter. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0040] It is also to be understood that, unless expressly stated to the contrary, in any method claimed herein that includes more than one step or act, the order of the method steps or acts is not necessarily limited to the order in which the method steps or acts are described.
[0041] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. The term "comprising" is defined inclusively, such that "including A or B" means including A, B, or A and B.
[0042] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive; that is, to include at least one of a number or list of elements, but including a plurality, and optionally additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (i.e., "one or the other, but not both") when preceded by a term of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.
[0043] Terms such as "comprises," "includes," "having," and the like are used interchangeably and have the same meaning. Similarly, terms such as "comprises," "includes," "having," and the like are used interchangeably and have the same meaning. Specifically, each term is defined consistent with the general U.S. Patent Law definition of "comprises," and therefore is to be interpreted as an open term meaning "at least the following," and not to exclude additional features, limitations, aspects, etc. Thus, for example, "an apparatus having elements a, b, and c" means that the apparatus includes at least components a, b, and c. Similarly, the phrase "a method including steps a, b, and c" means that the method includes at least steps a, b, and c. Additionally, although steps and processes may be outlined in a particular order herein, one of ordinary skill in the art will recognize that the ordering of steps and processes may vary.
[0044] As used in the specification and claims herein, the phrase "at least one" in connection with a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, may optionally be present, whether or not related to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer in one embodiment to at least one, optionally including two or more A, and no B (and optionally including elements other than B); in another embodiment to at least one, optionally including two or more B, and no A (and optionally including elements other than A); in yet another embodiment to at least one, optionally including two or more A, and at least one, optionally including two or more B (and optionally including other elements); and so forth.
[0045] As used herein, the terms "biological sample", "tissue sample", "specimen", and the like refer to any sample containing biomolecules (such as proteins, peptides, nucleic acids, lipids, carbohydrates, or combinations thereof) obtained from any organism, including viruses. Other examples of organisms include mammals (such as veterinary animals, such as humans, cats, dogs, horses, cows, and pigs, and laboratory animals, such as mice, rats, primates, and the like), insects, annelids, arachnids, marsupials, reptiles, amphibians, bacteria, and fungi, and the like. Biological samples include tissue samples (such as tissue sections or needle biopsies of tissues), cell samples (such as cytological smears, such as Pap smears or blood smears, or samples of cells obtained by microdissection), or cell fractions, fragments, or organelles (obtained by lysing cells and separating their components, such as by centrifugation). Other examples of biological samples include blood, serum, urine, semen, feces, cerebrospinal fluid, interstitial fluid, mucous membranes, tears, sweat, pus, biopsy tissue (e.g., obtained by surgical or needle biopsy), nipple aspirate, earwax, milk, vaginal fluid, saliva, swabs (such as cheek swabs), or any material that contains a biological molecule derived from an initial biological sample. In certain embodiments, the term "biological sample" as used herein refers to a sample prepared from a tumor or portion thereof obtained from a subject (such as a homogenized or liquefied sample).
[0046] As used herein, the term "biomarker" refers to a biological molecule found in blood, other bodily fluids, or tissues that is indicative of a normal or abnormal process, or a condition or disease, such as cancer. Biomarkers can be used to determine how well the body responds to treatment of a disease or condition, or whether a subject has a predisposition to a disease or condition. In the context of cancer, a biomarker refers to a biological substance that indicates the presence of cancer in the body. A biomarker can be a molecule secreted by a tumor, or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used in cancer diagnosis, prognosis, and epidemiology. Such biomarkers can be assayed in non-invasively collected biological fluids, such as blood or serum. Several gene and protein-based biomarkers are already used in patient care, including, but not limited to, AFP (liver cancer), BCR-ABL (chronic myeloid leukemia), BRCA1 / BRCA2 (breast / ovarian cancer), BRAF V600E (melanoma / colon cancer), CA-125 (ovarian cancer), CA19.9 (pancreatic cancer), CEA (colon cancer), EGFR (non-small cell lung cancer), HER-2 (breast cancer), KIT (gastrointestinal stromal tumor), PSA (prostate-specific antigen), S100 (melanoma), and many others. Biomarkers may be useful as diagnostics (identifying early cancer) and / or prognostic signs (predicting the aggressiveness of the cancer, predicting how a subject will respond to a particular treatment, and / or predicting the likelihood that the cancer will recur).
[0047] As used herein, the term "gating" refers to the selection of a population of particles from a sample based on particle characteristics. For example, particle characteristics can be defined based on forward scattering (FSC), side scattering (SSC), and / or fluorescence intensity. Thus, particles with the required characteristics pass the gate and are selected for further analysis, while particles without the required characteristics are not selected for further analysis. Digital gating means that after analyzing a mixture of all cells, a specific population is selected to be shown on a plot. The selected cell population is "digitally sorted" after analysis of all cells. Physical sorting is the process of removing a selected population from all cells into a separate tube and then analyzing the selected cell population. Both digital sorting and physical sorting are believed to achieve the analysis of a specific cell population as described herein.
[0048] As used herein, the term "homogenizing" refers to a process in which all fractions of a biological sample are rendered equal in composition. In the present disclosure, "homogenization" generally maintains the integrity of the majority of cells within the sample, e.g., at least 50, 80, 85, 90, 95, 96, 97, 98, 99, or 99.9% or more of the cells within the sample will not rupture or lyse as a result of the homogenization process. The homogenate may be substantially dissociated into individual cells (or clusters of cells), and the resulting homogenate or homogenates are substantially homogenous (consisting of or composed of similar elements, or uniform throughout).
[0049] As used herein, the term "labeling" or "staining" refers to a reagent that can bind to an analyte, be internalized or otherwise absorbed, and be detected, for example, by shape, morphology, color, fluorescence, luminescence, phosphorescence, absorbance, magnetic properties, or radioactive emission. Similarly, terms such as "labeling", "staining", etc., as used herein generally refer to any treatment of a biological specimen to detect and / or differentiate the presence, location, and / or amount (such as concentration) of a particular molecule (such as a lipid, protein, or nucleic acid) or a particular structure (such as a normal or malignant cell, cytosol, nucleus, Golgi apparatus, or cytoskeleton) in the biological specimen. For example, staining can provide contrast between a particular molecule or a particular cellular structure and the surrounding parts of the biological specimen, and the intensity of the staining can provide a measure of the amount of a particular molecule in the specimen. Staining can be used to aid in the observation of molecules, cellular structures, and organisms using bright field microscopes as well as other observation tools such as phase contrast microscopes, electron microscopes, and fluorescence microscopes. Some staining performed by the system can be used to visualize the contours of cells. Other staining performed by the system can depend on the particular cellular component (such as a molecule or structure) to be stained, with no or relatively little staining of other cellular components. Examples of types of staining methods performed by the system include, but are not limited to, histochemical methods, immunohistochemical methods, and other methods based on reactions between molecules (including non-covalent interactions), such as hybridization reactions between nucleic acid molecules. Specific staining methods include, but are not limited to, primary staining methods (e.g., H&E staining, Pap staining, etc.), enzyme-linked immunohistochemical methods, and in situ RNA and DNA hybridization methods, such as fluorescence in situ hybridization (FISH).
[0050] As used herein, the terms "representative sample" and "representative sampling" refer to a sample (or a subset of samples) that accurately reflects the overall composition, and thus the sample is an unbiased indicator of the entire population. In general, this means that the different cell types and their relative proportions or percentages within a representative sample or a portion thereof essentially accurately reflect or mimic the relative proportions or percentages of these cell types within an entire tissue specimen, typically a solid tumor or a portion thereof. As used herein, "sequencing" or "DNA sequencing" refers to a biochemical method for determining the order of the nucleotide bases, adenine, guanine, cytosine, and thymine, in a DNA oligonucleotide. As used herein, sequencing may include, without limitation, parallel sequencing or any other sequencing method known to those skilled in the art, such as chain termination reaction, rapid DNA sequencing, wandering-spot analysis, Maxam-Gilbert sequencing, dye terminator sequencing, or using any other modern automated DNA sequencing device.
[0051] As used herein, the term "tumor" refers to a mass or neoplasm, defined as an abnormal new growth of cells that usually grows more rapidly than normal cells and continues to grow if untreated, possibly resulting in damage to adjacent structures. Tumors can vary in size. Tumors can be solid or filled with fluid. Tumors can refer to benign (non-malignant, generally harmless) or malignant (possible metastasis) growths. Some tumors can contain benign blast cells (such as intraepithelial carcinoma) and malignant cancer cells (such as adenocarcinoma) at the same time. This should be understood to include neoplasms located in multiple sites throughout the body. Thus, for purposes of disclosure, tumors include primary tumors, lymph nodes, lymphatic tissue, and metastatic tumors.
[0052] As used herein, the term "tumor sample" includes a sample prepared from a tumor or a sample potentially containing or suspected of containing cancer cells, or that is being tested for the potential presence of cancer cells, such as lymph nodes.
[0053] Isolation of cells and / or nuclei from tissue
[0054] 1 and 3, in some embodiments, cells, nuclei, and / or small tissue aggregates are separated from a sample, such as a tissue sample. In some embodiments, cells, nuclei, and / or small tissue aggregates are separated from a tissue sample by homogenizing the tissue sample (step 100). In some embodiments, cells, nuclei, and / or small tissue aggregates present in the homogenized sample are then submitted for flow cytometric analysis (step 110). The dissociated cells, nuclei, and / or small tissue aggregates may then be gated (step 120) and subsequently further analyzed.
[0055] In some embodiments, the tissue sample for homogenization (step 100) is derived from a tumor (cancerous or non-cancerous), a metastatic lesion, normal tissue, whole blood, or lymph node. In some embodiments, the tissue sample is a residual surgical sample, a biopsy sample, or a histological sample. In some embodiments, the tissue sample is a fresh sample, i.e., a non-preserved sample. In some embodiments, the tissue sample is a fixed tissue sample. In some embodiments, the tissue sample is derived from a formalin-fixed paraffin-embedded tissue sample block. In some embodiments, multiple tissue sources can be combined and then cells and / or nuclei can be isolated from the collective tissue sample.
[0056] Homogenization of tissue samples
[0057] In some embodiments, tumor samples, lymph node samples, and / or other tissue samples are homogenized (step 300) by placing the sample in a mechanical disruption device, such as a blender or ultrasonicator. Homogenization produces extensive tissue fragments. Methods for preparing homogenized tumor or lymph node samples are disclosed in PCT Application No. PCT / US2016 / 060861, which is incorporated herein by reference in its entirety.
[0058] Following sufficient mechanical disruption to separate the tumor, lymph node, and / or other tissue sample, all subpopulations of tumor cells that were originally spatially separated within the original sample are distributed throughout the new homogenized sample. That is, as a result of homogenizing a tumor, one or more lymph nodes, or any combination thereof, any cellular heterogeneity within the tumor is substantially homogenously (uniformly) distributed within the resulting homogenate or a portion or fraction thereof, such that the homogenate (or any fraction thereof) substantially homogenously expresses the heterogeneity of the input tumor and / or lymph node sample. By homogenizing a tumor and / or lymph node to generate a sample (or homogenate) representative of the tumor in its entirety, in some embodiments, it may be possible to characterize the landscape (e.g., heterogeneity) of the tumor, for example to analyze each of the different cell or nuclear populations contained within the entire homogenate (e.g., to determine the amount of a particular type of immune cell to determine whether a patient is a candidate for a particular type of treatment). In some embodiments, the methods are useful for detecting tumor infiltrating lymphocytes, such as the relative abundance of different tumor infiltrating lymphocytes.
[0059] Dissociation of cells, nuclei, and / or small tissue aggregates from tumors
[0060] The homogenized sample (from step 200) can be further dissociated and / or processed to obtain dissociated cells, nuclei, and / or small tissue aggregates (step 210). In general, there are three main methods for tissue dissociation, including enzymatic dissociation, chemical dissociation, and mechanical dissociation, or any combination thereof. The choice of dissociation method is usually based on the tissue type and tissue origin.
[0061] Enzymatic dissociation is the process of using enzymes to digest tissue fragments, thereby releasing cells from the tissue. Many different types of enzymes can be used in this process, and as one skilled in the art will understand, certain enzymes are more effective for certain tissue types. One skilled in the art will also understand that any enzymatic dissociation process can use one or more enzymes in combination with each other, or may use one or more enzymes in combination with other chemical and / or mechanical dissociation methods. Examples of suitable enzymes include, but are not limited to, collagenase, trypsin, elastase, hyaluronidase, papain, DNase I, neutral protease, and trypsin inhibitor.
[0062] Collagenase is a proteolytic enzyme used to digest proteins found in the extracellular matrix. Collagenase, characteristic of the enzyme protease, is able to attack and degrade the triple-helical native collagen fibrils commonly found in connective tissues. There are four basic collagenase types: type 1, which is suitable for use with epithelial, liver, lung, adipose, and adrenal tissue cell specimens; type 2, which has high proteolytic activity and is therefore suitable for use with tumor-derived tissues from heart, bone, muscle, thyroid, and cartilage; type 3, which has low proteolytic activity and is therefore suitable for use with breast cells; and type 4, which, due to its tryptic activity, is suitable for pancreatic islets and other research protocols where receptor integrity is important.
[0063] Trypsin has been described as a pancreatic serine (amino acid) protease with specificity for peptide bonds involving the carboxyl groups of arginine and lysine amino acids. It is considered one of the most specific proteases. Trypsin alone is usually ineffective for tissue dissociation because it has little selectivity for extracellular proteins. It is usually used in combination with other enzymes such as collagenase or elastase.
[0064] Elastase is another pancreatic serine protease with specificity for peptide bonds adjacent to neutral amino acids. Its ability to hydrolyze native elastin is unique among proteases. Elastase can also be found in blood components and bacteria. In some embodiments, it is suitable for the isolation of type II cells from lung tissue.
[0065] Hyaluronidase is a polysaccharidase that is often used in tissue dissociation, typically in combination with cruder proteases such as collagenase, that has affinity for the bonds found in almost all connective tissues.
[0066] Papain is a sulfhydryl protease with broad specificity that allows it to degrade most protein substrates more completely than the pancreatic proteases trypsin or elastase. Papain is often used to isolate nerve material from tissues.
[0067] Deoxyribonuclease I (DNase I) is often included in enzymatic cell isolation procedures to digest nucleic acids that can leak into the dissociation medium and increase viscosity and recovery problems. Without wishing to be bound by theory, it is believed that DNase I does not damage intact cells.
[0068] Neutral proteases, such as Dispase® (available from Worthington Biochemical), are bacterial enzymes with mild proteolytic activity; Dispase® is useful for isolating primary and secondary cell cultures due to its ability to maintain cell membrane integrity. It has been found to dissociate fibroblast-like cells more efficiently compared to epithelial-like cells. It is inhibited by EDTA.
[0069] Trypsin inhibitors, primarily derived from soybean, inactivate trypsin and are therefore sometimes used in certain cell isolation protocols.
[0070] Chemical dissociation takes advantage of the fact that cations are involved in intracellular bonds and in maintaining the intracellular matrix. By introducing EDTA or EGTA, which bind to these cations, the intercellular bonds are disrupted, thereby allowing dissociation of the tissue structures.
[0071] Finally, mechanical dissociation entails cutting, scraping, or scratching the tissue into small pieces, and then washing the minced tissue in medium to separate the cells from the tissue, sometimes also using gentle agitation and / or sonication to help loosen the cells. In other embodiments, mechanical dissociation can include homogenization of the sample, as further described herein.
[0072] In some embodiments, cells within a homogenized sample or a filtered homogenized sample are lysed to release cellular components. For example, cells may be lysed using a French press or similar type of lysing device, a microfluidizer, grinding, trituration, chemical or enzymatic lysis (including those described above), and / or other techniques known in the art. In some embodiments, membrane lipids and proteins (including histones) are removed from the sample containing cellular components (e.g., by adding detergents or enzymes (proteases)).
[0073] Further processing of homogenized, representative, or dissociated samples into individual nuclei requires the removal of cell membranes. Current nuclear isolation methods for fresh cells do not require enzymes to release nuclei, and nuclear isolation from formalin-fixed samples is not a common method. To efficiently isolate individual nuclei, enzymes (e.g., pronase, proteinase K, pepsin, trypsin, Accumax, collagenase H) can be used to reveal nuclei without excessive damage that would release DNA from the processed nuclei, while maintaining cytoskeleton markers that allow for differentiation between normal and tumor nuclei. Specific methods for isolating nuclei from homogenates or representative samples are disclosed in co-pending PCT Application No. PCT / US2016 / 060861, the entirety of which is incorporated herein by reference.
[0074] In some embodiments, the homogenate is further mixed in a typical blender (IKA blender) and then filtered through a set of cell strainers of different sizes (e.g., about 20 um, about 10 um, etc.). In some embodiments, a metal mesh is used to remove large tissue fragments before filtering through the cell strainers. In some embodiments, the resulting sample is composed primarily of single cells (several small cells aggregated as doublets) that can be stained with a desired marker.
[0075] Staining of cells within homogenized samples
[0076] In some embodiments, the dissociated cells and / or nuclei are labeled or stained prior to evaluating the sample by flow cytometry so that different cell types can be identified (see, e.g., FIG. 12). The label or stain can be any detectable label or reporter moiety, e.g., a fluorescent label, that can identify different cell types by flow cytometry (step 310 of FIG. 3).
[0077] In some embodiments, the homogenized sample is contacted with one or more detection probes, which can be visualized by applying one or more detection reagents (see, e.g., PCT Publication No. WO / 2017 / 085307, the disclosure of which is incorporated herein by reference in its entirety). For example, in some embodiments, the detection probe utilized is specific for an immune cell marker. In some embodiments, the detection probe is selected from primary antibodies specific for markers of lymphocytes, including T lymphocytes and B lymphocytes. In other embodiments, the detection probe is selected from primary antibodies specific for markers of leukocytes, helper T cells, regulatory T cells, and / or cytotoxic T cells. In yet other aspects, the detection probe is selected from primary antibodies specific for broad spectrum lymphocyte secondary biomarkers.
[0078] In some embodiments, the antibodies can be conjugated to different fluorochromes by any conventional procedure, such as that described by Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens," in Selected methods in Cellular Immunology, eds. BB Mishell and SM Siigi, WH Freeman and Co. (1980). For example, different immune cell types can be determined using fluorescently labeled antibodies specific for antigens on the different cell types. Examples of fluorescently labeled antibodies specific for different cell types include, but are not limited to, CD3 FITC / CD16+CD56PE for NK cells; CD3 FITC / CD19PE for B cells; CD45 FITC / CD14PE for monocytes; CD3 FITC / CD4PerCP for helper T cells; CD3 FITC / CD8PE for CD8 cells; CD4PerCP / CD45 RO PE for helper memory T cells; CD8 FITC / CD45RO PE for CD8 memory cells; CD62 FITC / CD45RA PE / CD4PerCP for naive helper T cells; CD62 FITC / CD45RA PE / CD8PerCP for naive CD8 cells. In other embodiments, cells or nuclei are stained with 4',6-diamidino-2-phenylindole (DAPI).
[0079] In some embodiments, the detection probe is selected from primary antibodies specific for certain receptors and / or ligands, including, but not limited to, CD45, CD45LCA (where "LCA" refers to leukocyte common antigen), CD3, CD4, CD8, CD20, CD25, CD19, and CD163 (e.g., anti-CD antibodies). In other embodiments, the detection probe is a primary antibody specific for CD45LCA. In some embodiments, the detection probe is an anti-CD45LCA primary antibody available from Ventana Medical Systems (Tucson, AZ) and available under the trade name CONFIRM anti-CD45, LCA (RP2 / 18) (a mouse monoclonal antibody (IgGI) that specifically binds to an antigen located on the membrane of leukocytes).
[0080] In some embodiments, the sample is stained for the presence of at least lymphocyte markers. Lymphocyte markers include CD3, CD4, and CD8. In general, CD3 is the "universal marker" for T cells. In some embodiments, further analysis (staining) is performed to identify specific types of T cells, e.g., regulatory, helper, or cytotoxic T cells. For example, CD3+ T cells can be further differentiated as cytotoxic T lymphocytes positive for the CD8 biomarker (CD8 is a specific marker for cytotoxic T lymphocytes). CD3+ T cells can also be differentiated as cytotoxic T lymphocytes positive for perforin (perforin is a membrane-degrading protein expressed in the cytoplasmic granules of cytotoxic T cells and natural killer cells). Cytotoxic T cells are the effector cells that actually "kill" the tumor cells. They are believed to directly contact and introduce the digestive enzyme granzyme B into the cytoplasm of tumor cells, thereby killing the tumor cells. Similarly, CD3+ T cells can be further differentiated as regulatory T cells that are positive for the FOXP3 biomarker. FOXP3 is a nuclear transcription factor that is the most specific marker for regulatory T cells. Similarly, CD3+ T cells can be further differentiated as helper T cells that are positive for the CD4 biomarker.
[0081] In view of the above, in some embodiments, the homogenized sample may be stained for one or more immune cell markers, including at least CD3 or total lymphocytes, as detected by hematoxylin and eosin staining. In some embodiments, at least one additional T cell specific marker may also be included, such as CD8 (a marker for cytotoxic T lymphocytes), CD4 (a marker for helper T lymphocytes), FOXP3 (a marker for regulatory T lymphocytes), CD45RA (a marker for naive T lymphocytes), and CD45RO (a marker for memory T lymphocytes). In a specific embodiment, at least two markers are used, including human CD3 (or total lymphocytes, as detected by H&E staining) and human CD8.
[0082] In some embodiments, T cells, e.g., CD8 positive cytotoxic T cells, may be further differentiated by various biomarkers including PD-1, TIM-3, LAG-3, CD28, and CD57. Thus, in some embodiments, T cells are stained with at least one of various lymphocyte biomarkers for their identification (e.g., CD3, CD4, CD8, FOXP3) and additional biomarkers for further differentiation (LAG-3, TIM-3, PD-L1, etc.).
[0083] Gating cell populations
[0084] Following isolation of cells, nuclei, and / or small tissue aggregates from the tissue sample, or more specifically, following homogenization (step 300) and staining of the cells, nuclei, and / or small tissue aggregates (step 310), the cells, nuclei, and / or small tissue aggregates are provided for flow cytometric analysis. In some embodiments, the sample is electronically or virtually sorted (step 120 of FIG. 1; steps 320 and 330 of FIG. 3).
[0085] In some embodiments, flow cytometry data from homogenized samples (e.g., a population of total cells dissociated from a whole tumor, including immune cells, tumor cells, and epithelial cells) is considered to be of "low quality" due to the nature of the heterogeneous cell population analyzed. This heterogeneous population of analyzed cells consists of cells with different sizes and granularity that are not "organized" in different populations as is "typical" in flow cytometry data. Since flow cytometry analysis is mainly based on the observation of distinct cell populations on a dot plot, data from homogenized samples are considered to look "strange" without being able to define distinct cell populations. When gating on small cells, more homogeneous cell populations (e.g., immune cells that have similar size and granularity and result in distinct populations on a dot plot) can be analyzed, so that the data looks more similar to traditional flow cytometry data (e.g., distinct populations) and the increase in fluorescence due to staining of a particular subpopulation of an immune cell population may be easier to depict. This gating does not change the data, i.e., it only depicts the data in a way that flow cytometry users are accustomed to. The gating process allows one to see specific cell populations (e.g., immune cells) even when analyzing a mixture of all cells in a sample. The resulting selected cell populations are therefore more homogenous in size and granularity and presented as distinct cell populations on the flow cytometry data plot.
[0086] In some embodiments, the present disclosure provides a gating scheme whereby a homogenized mixture of cells or nuclei is first gated based on size (primary gating) (step 200) to provide a first population of cells or nuclei having a first size range or predicted cell type, and then gated a second time based on at least the expression of a biomarker (secondary gating) (step 210). The primary and / or secondary gating can each be performed one or multiple times.
[0087] In some embodiments, primary gating is performed to distinguish one or more cell populations based on forward scatter (FSC) and side scatter (SSC) characteristics. Forward scatter and side scatter may provide an estimate of cell size and granularity, respectively, which may depend on several factors, such as the sample, the wavelength of the laser, the collection angle and the refractive index of the sample and sheath fluid. In some embodiments, distinguishing cell populations may be more straightforward for cell lines where only one cell type is present (see FIG. 5A), but more complex for samples where multiple cell types are present, such as in homogenized tissue samples. That is, cellular heterogeneity in homogenized samples significantly reduces the quality of flow cytometry data (compare FIG. 5A and FIG. 5B). FIG. 5A and FIG. 5B show stained samples, while FIG. 6A and FIG. 6B show forward scatter vs. side scatter (no markers shown).
[0088] In embodiments where the homogenized sample is derived from a tumor sample, one skilled in the art will recognize that the homogenized sample will contain a population of tumor cells and other populations of cells, such as immune cells. Applicant has previously shown that such cell populations can be physically sorted (see PCT Application No. PCT / EP2018 / 058809, the entire disclosure of which is incorporated herein by reference). One skilled in the art will appreciate that a scatter-based gating strategy can be utilized to digitally sort those cells in the tumor cell population from those cells in other populations present within the homogenized sample.
[0089] In some embodiments, such a primary gating strategy allows for the selection of cells having a particular predicted size range (e.g., about 3 μm to about 6 μm in size) or predicted cell type (e.g., immune cells). In some embodiments, the relative proportions of cells having a second size (e.g., tumor cells that are greater than 12 μm in size) and a second size (e.g., immune cells that are less than 12 μm in size) can be determined and / or quantified by placing a gate in an area of the density plot where the distinct populations would be estimated or predicted. For example, if it is desired to determine the proportions of different types of immune cells within a homogenized tumor sample, the operator can select a primary gating trace that takes into account characteristics of immune cells that are distinct from tumor cells, e.g., size differences between immune cells and tumor cells.
[0090] As shown in the bi-parameter density plot of FIG. 6, the primary gating strategy (step 200 or step 330) can be selected such that small cells can be separated from large cells, including tumor cells, based on forward and side scatter. As shown in FIG. 6, relatively small immune cells can be digitally separated from large tumor cells, both present in the homogenized tumor sample, by tracing a gate (a gate that estimates the physical properties of immune cells compared to other cells of the sample) on the bi-parameter density plot of FSC vs. SSC. In some embodiments, considering that immune cells are relatively smaller than tumor cells, the upper limit of the gate trace on the forward scatter axis is selected such that the cell population generated after primary gating is enriched with smaller immune cells (see step 400 of FIG. 4). Similarly, considering that immune cells are less complex and therefore less granular than tumor cells, the upper limit of the side scatter is selected to provide a population enriched for those cells with reduced granularity compared to tumor cells (see step 410 of FIG. 4).
[0091] To confirm that the primary gating in the above example properly predicted the population of immune cells (i.e., immune cells digitally separated from tumor cells in a homogenized sample), a plot of FSC vs. biomarker staining intensity was generated for two different cell populations derived from the same sample (large and small cell populations) for the same marker (CD3). FIG. 8A provides a density plot of FSC vs. CD3 biomarker staining showing the presence of cells in the predicted immune cell populations returned after primary gating. Control samples are comparatively accounted for in each population in the absence of staining with antibodies targeting CD3. Similarly, FIG. 8B provides a density plot of FSC vs. CK8 / 18 tumor biomarker staining showing the presence of cells in the predicted tumor cell populations returned after primary gating. Again, control samples are comparatively accounted for in each population in the absence of staining with antibodies targeting CK8 / 18 tumor biomarker. By comparing FIG. 8A and FIG. 8B, it is clear that the gating strategy properly predicts immune cell populations based on the size of the cells.
[0092] The utility of primary gating in predicting cell populations derived from heterogeneous homogenized tumor samples based on size and / or granularity is further illustrated in FIG. 7, which shows five different gate traces (labeled 1, 2, 3, 4, and 5) performed on a single homogenized sample. Each gate trace, i.e., traces 1, 2, 3, 4, and 5, was selected to provide a different cell population with different characteristics based on scatter. In this particular example, gates were selected based on traces that were likely to have aneuploidy, i.e., the presence of an abnormal number of chromosomes. Knowing that such abnormal cells were likely to be tumor cells and therefore large, gates 4 and 5 were traced to obtain a population enriched for large cells. Compared to gate trace 1 (predicted to have small cells such as immune cells), in which only 0.64% of cells had aneuploidy, 13.22% and 8.89% of cells in the subpopulations generated by gate traces 4 and 5 had aneuploidy. 2.14% and 2.32% of cells in traces 2 and 3, respectively, had aneuploidy based on the trace selection predicted to encompass those cells with higher granularity compared to the trace selected for gate 1. Here, the optimal gate to capture the subpopulation with the most cells with aneuploidy was gate 4, taking into account the high granularity and large cell size that were believed to be characteristic of cells with aneuploidy. Applicants have shown that primary gating based on forward and side scatter provides a better estimate of aneuploidy than primary gating based on the presence of tumor markers (e.g., CK8 / 18) as described in Example 3.
[0093] In some embodiments, secondary gating (step 210 or step 240) is performed to determine the expression pattern of specific cell types from within the cell population identified during the primary gating. This may be particularly useful when the number of biomarkers is increased. For example, successive secondary gating (step 350, shown by dashed lines) can be used in multiplex assays to identify specific cell subpopulations expressing different biomarkers in the homogenized sample. In some embodiments, each secondary gating is performed by applying a trace to a biparameter density plot of forward scatter (FSC) versus biomarker staining intensity in the first cell population identified after the primary gating step.
[0094] As an example, lymphocytes may be identified by performing a primary gating based on forward and side scatter (see FIG. 6). A first secondary gating may be performed to identify and quantify CD3 positive T cells (FIG. 9A). A second and third secondary gating may be performed to differentiate CD3 positive T cells based on CD4 and CD8 expression as well (see FIG. 9B-9C). In this particular example, three secondary gatings are performed and traces with specific intensity cutoffs are applied to identify those subpopulations expressing each of the CD3, CD8, and CD4 biomarkers. The percentage of biomarker expression for each subpopulation may also be determined after secondary gating. FIG. 10 illustrates the generation of the percentage of CD8 positive immune cells derived from homogenized samples from different patient samples. In some embodiments, this type of data may be used to quantitatively measure the expression of different markers from whole tumor samples dissociated into single cells. In some embodiments, these expression levels could be correlated with the diagnosis, prognosis, and treatment status of the patient. In some embodiments, flow cytometry is more quantitative than IHC and is amenable to multiplexing. In some embodiments, the fact that the whole tumor is analyzed can account for increased tumor heterogeneity and provide better correlation. Applicant has shown that such data obtained by the method of the present invention compares well with data obtained from actual physical sorting methods such as those described in Example 1.
[0095] In some embodiments, the same or different gates are selected for each marker depending on the variability between flow cytometry runs. Gates are then selected that help identify positive cells (cells that are absent in the control and only appear in the sample). In some processes, the process is automated using computer-implemented algorithms.
[0096] The above principles can be extended to other biomarkers to identify and / or quantitate other types of immune cells, as well as to identify further subpopulations within any population or subpopulation. For example, the relative expression of CD28 and CD45RA biomarkers can be used to identify CD45RA+CD28+ naive cells, CD45RA-CD28+ memory cells, and CD45RA+CD28- effector cells based on the CD4 and CD8 populations. This principle can be continued with further additional markers.
[0097] The above identified methods are not limited to quantifying the amount or relative amount of cells expressing a cluster of differentiation markers. In some embodiments, the above methods can be applied to determine the proportion of certain types of immune cells in different patients, and for example, (i) to determine whether those patients will benefit from, for example, a certain type of treatment, or (ii) to monitor tumor progression and / or treatment. In other embodiments, the disclosed methods can be utilized to identify new correlations between the expression of two or more biomarkers or between the expression of a biomarker and chromosomal abnormalities, as described in Example 2. EXAMPLES
[0098] Example 1 – Comparison of physical and digital sorting
[0099] The results of the physical sorting process were compared with the results of the digital gating method according to the method described herein. The physically sorted small cells were analyzed for the CD3 marker (small cells from the total homogenate). The small cells (immune cells) expressed the CD3 marker as expected (see panel B of FIG. 11, showing a separate and distinct CD3 population (73.71% positive cells). Overall, FIG. 11 shows that the physical and digital sorting methods give similar results. All cells from the dissociated tumor were stained for CD3 and DAPI, analyzed by flow cytometry, and the small cells (immune) were gated. This is shown in panel A of FIG. 11. Gating is a method of looking at a population (herein immune cells) within a mixed cell population. All cells from the dissociated tumor were stained only for DAPI and then analyzed by flow cytometry. The small cells (immune cells) were sorted (physically separated from the cell mixture), stained for CD3, and then analyzed again by flow cytometry. The data are shown in panel A of FIG. 11. The percentages in both cases also represent the percentage of positive cells within the analyzed population. In the case of panel A of FIG. 11, the percentages were quite high since the analyzed population was sorted cells (pure sample). In the case of panel B of FIG. 11, the percentages were lower since the analyzed sample was gated on a less pure small cell population (some large cells may find their way in the analyzed population). Panel C of FIG. 11 illustrates the analysis of the same cell mixture without gating or sorting. The quality of the data was poorer (unclear positive cell population with a low percentage of smear).
[0100] Example 2 - Correlation of Cells Identified as CD8+ with Aneuploidy
[0101] Tumor aneuploidy and tumor infiltrating lymphocytes are believed to be inversely proportional in different cancer types. Using tumor homogenates and flow cytometry, samples were analyzed for both aneuploidy and tumor infiltrating lymphocytes, and the same correlation was observed. For example, the same whole tumor was homogenized and filtered according to the techniques described herein. An aliquot of dissociated cells was then stained for the presence of CD3 or CD3 and also stained with DAPI (2-(4-amidinophenyl)-1H-indole-6-carboxamidine). The stained samples were submitted for flow cytometry analysis, and the data obtained was analyzed for aneuploidy (from DAPI) and markers (CD3 or CD8). The sample process was repeated for different cancer types, e.g., lung cancer and colon cancer. Tumor aneuploidy and tumor infiltrating lymphocytes were again observed to be inversely proportional in different cancer types.
[0102] Example 3 - Comparison of primary gating based on scatter with primary gating based on biomarker expression
[0103] FIG. 7 provides a dot plot showing forward and lateral size (size vs. granularity). When analyzing different locations on the plot, aneuploidy was observed to increase with size and granularity, which was expected since tumor cells are relatively larger or more granular than aneuploid cells. The same analysis was also performed (FIG. 13), but using a dot plot showing CK8 / 18 staining vs. forward scatter. Large cells were determined to be more aneuploid as expected, and CK8 / 18 was also expected to be more aneuploid. Size was also determined to be an even better predictor of tumor cells than CK8 / 18, since small cells considered CK8 / 18 positive (bottom right quarter of FIG. 13) had few aneuploids, meaning they were more likely to be non-tumor cells. All large cells (CK8 / 18 positive or negative) had more aneuploidy, meaning they were tumor cells. Both FIG. 7 and FIG. 13 confirm that proper gating on size was sufficient to define cells as tumor or immune, without the need for staining for tumor biomarkers.
[0104] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to herein and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety. Aspects of the embodiments can be modified, if necessary, to employ concepts from the various patents, applications, and publications to provide further embodiments.
[0105] Although the present disclosure has been described with reference to certain exemplary embodiments, it should be understood that numerous other modifications and embodiments may be devised by those skilled in the art that would fall within the spirit and scope of the principles of the present disclosure. More specifically, reasonable variations and modifications are possible in the components and / or arrangements of the combined configurations of the subject matter within the scope of the foregoing disclosure, the drawings, and the appended claims without departing from the spirit of the present disclosure. In addition to modifications and changes in the components and / or arrangements, alternative uses will also be apparent to those skilled in the art.
Claims
1. 1. A method for quantifying a proportion of cells expressing at least a first of one or more biomarkers in a sample, comprising: staining the cells in the sample for the presence of the one or more biomarkers; performing at least two successive gatings to provide at least a first subpopulation of cells expressing said first of said one or more biomarkers, wherein said at least two successive gatings include a primary gating to provide a first cell population and a secondary gating to provide a first cell subpopulation, said primary gating being based on forward scatter and side scatter, and a cutoff being selected for forward scatter such that said first cell population is enriched with immune cells; determining a first proportion of cells in said first subpopulation that express said first of said one or more biomarkers.
2. 10. The method of claim 1, wherein the immune cells are less than about 12 μm in size.
3. The method of claim 1 , wherein multiple secondary gating is performed.
4. The method of claim 1 , wherein the one or more biomarkers are a cluster of differentiation biomarkers and the secondary gating is performed based on expression of the one or more cluster of differentiation biomarkers.
5. 2. The method of claim 1, wherein the cluster of one or more differentiation biomarkers is selected from the group consisting of CD3, CD4, CD8, CD45RA, CD45RO, CD28, and CD57.
6. The method of claim 1, further comprising determining a proportion of a second cell in a second cell subpopulation that expresses a second of the one or more biomarkers, wherein the first and second of the one or more biomarkers are different.
7. The method of claim 6 , wherein the second of the one or more biomarkers is a biomarker other than a cluster of differentiation biomarkers.
8. 8. The method of claim 7, wherein said second of said one or more biomarkers is selected from the group consisting of PD-1, TIM-3, LAG-3, and FOXP3.
9. The method of claim 1 , wherein the sample comprises a homogenized sample.
10. 10. The method of claim 9, wherein the homogenized sample is prepared by: (i) obtaining a tissue sample; and (ii) mechanically disrupting cells from the obtained tissue sample.
11. 10. The method of claim 9, wherein the homogenized sample is derived from a fixed tissue sample.
12. 2. The method of claim 1, wherein the at least two successive gatings include a gating that identifies cells based on size.
13. The method of claim 12, wherein the at least two successive gatings include a gating that identifies cells based on expression of the one or more biomarkers.
14. 14. The method of claim 13, further comprising correlating expression of the one or more biomarkers with a diagnostic, prognostic, and / or therapeutic status of the subject from which the sample is derived.
15. The method of claim 1, wherein the sample is fixed.
16. The method of claim 9, wherein the homogenized sample is derived from a formalin-fixed paraffin-embedded (FFPE) sample.
17. The method of claim 9, wherein the homogenized sample is derived from mechanical disruption of a sample.
18. The method of claim 17, wherein the mechanical disruption comprises placing the fixed tissue sample in a blender or ultrasonicator.
19. The method of claim 18, further comprising filtering the sample.
20. The method of claim 9, wherein the homogenized sample is derived from enzymatic dissociation of a sample.
21. The method of claim 9, wherein the homogenized sample is derived from: (i) mechanically disrupting a fixed tissue sample to provide a mechanically disrupted sample; and (ii) enzymatically dissociating the mechanically disrupted sample.
22. The method of claim 1, wherein the sample comprises a dissociated single cell.
23. The method of claim 9, wherein the homogenized sample comprises dissociated single cells.
Citation Information
Patent Citations
Representative diagnostics
WO2017079763A1
Improved cytometric assays
WO2017094008A1
Methods of detecting per cell PD-l1 expression and uses thereof
WO2018048936A1
